JP2016504400A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016504400A5 JP2016504400A5 JP2015552060A JP2015552060A JP2016504400A5 JP 2016504400 A5 JP2016504400 A5 JP 2016504400A5 JP 2015552060 A JP2015552060 A JP 2015552060A JP 2015552060 A JP2015552060 A JP 2015552060A JP 2016504400 A5 JP2016504400 A5 JP 2016504400A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound
- aryl
- pharmaceutically acceptable
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 20
- 150000001875 compounds Chemical class 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 11
- 229910052731 fluorine Inorganic materials 0.000 claims 10
- 125000000623 heterocyclic group Chemical group 0.000 claims 9
- 125000003710 aryl alkyl group Chemical group 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 229910052801 chlorine Inorganic materials 0.000 claims 4
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 208000034757 axonal type 2FF Charcot-Marie-Tooth disease Diseases 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 210000004081 cilia Anatomy 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002207 retinal effect Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1300435.3 | 2013-01-10 | ||
| GBGB1300435.3A GB201300435D0 (en) | 2013-01-10 | 2013-01-10 | Benzylideneguanidine Derivatives and Therapeutic Use for the Treatment of Protein Misfolding Diseases |
| PCT/EP2014/050422 WO2014108520A1 (en) | 2013-01-10 | 2014-01-10 | Benzylideneguanidine derivatives and therapeutic use for the treatment of protein misfolding diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016504400A JP2016504400A (ja) | 2016-02-12 |
| JP2016504400A5 true JP2016504400A5 (enExample) | 2017-01-05 |
| JP6276289B2 JP6276289B2 (ja) | 2018-02-07 |
Family
ID=47757796
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015552060A Active JP6276289B2 (ja) | 2013-01-10 | 2014-01-10 | ベンジリデングアニジン誘導体、及びタンパク質ミスフォールディング疾患を治療するための治療的使用 |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US9682943B2 (enExample) |
| EP (2) | EP3115357B1 (enExample) |
| JP (1) | JP6276289B2 (enExample) |
| KR (1) | KR102166665B1 (enExample) |
| CN (1) | CN105189452B (enExample) |
| AU (2) | AU2014204831C1 (enExample) |
| CA (1) | CA2896976C (enExample) |
| DK (1) | DK2943467T3 (enExample) |
| ES (2) | ES2831453T3 (enExample) |
| GB (1) | GB201300435D0 (enExample) |
| HR (1) | HRP20161208T1 (enExample) |
| HU (1) | HUE030848T2 (enExample) |
| IL (1) | IL239629B (enExample) |
| LT (1) | LT2943467T (enExample) |
| MX (1) | MX370491B (enExample) |
| PL (1) | PL2943467T3 (enExample) |
| PT (1) | PT2943467T (enExample) |
| RS (1) | RS55185B1 (enExample) |
| RU (1) | RU2654910C2 (enExample) |
| SI (1) | SI2943467T1 (enExample) |
| WO (1) | WO2014108520A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201300435D0 (en) * | 2013-01-10 | 2013-02-27 | Medical Res Council | Benzylideneguanidine Derivatives and Therapeutic Use for the Treatment of Protein Misfolding Diseases |
| US10905663B2 (en) | 2013-03-05 | 2021-02-02 | The University Of Chicago | Treatment of demyelinating disorders |
| CA2951191C (en) | 2014-07-02 | 2022-09-13 | Inflectis Bioscience | Novel therapeutic uses of benzylideneguanidine derivatives for the treatment of proteopathies |
| DK3280404T3 (da) | 2015-04-08 | 2021-11-08 | Res & Innovation Uk | Fremgangsmåder til valg af phosphatase-selektive og ikke-selektive phosphatasehæmmere |
| US9501793B1 (en) * | 2015-06-04 | 2016-11-22 | Herofi, Inc. | Archetecture and associated methodology for data standardization and utilization in retail industry applications |
| AU2016304331B2 (en) * | 2015-07-31 | 2021-08-05 | Inflectis Bioscience | Method of treating cancer with a combination of benzylideneguanidine derivatives and chemotherapeutic agent. |
| US20180230105A1 (en) | 2017-01-13 | 2018-08-16 | Regents Of The University Of Minnesota | Therapeutic compounds |
| US11166464B2 (en) * | 2017-03-06 | 2021-11-09 | The United States Of America, As Represented By The Secretary Of Agriculture | Self-assembled active agents |
| WO2019215470A1 (en) | 2018-05-09 | 2019-11-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of guanabenz or derivates thereof for the treatment of type i ifn-dependent pathologies |
| CN113072467B (zh) * | 2021-03-24 | 2022-04-12 | 南方医科大学 | 含取代胍基衍生物及其在制备破骨细胞分化抑制剂上的应用 |
| WO2024105168A1 (en) | 2022-11-18 | 2024-05-23 | Inflectis Bioscience | Novel combinations useful for the treatments of als |
| US20240293343A1 (en) | 2023-02-13 | 2024-09-05 | Inflectis Bioscience | Benzylideneaminoguanidine derivatives as NR2B-selective NMDA receptor antagonists and their therapeutic applications |
| KR20250157531A (ko) * | 2023-03-16 | 2025-11-04 | 교토후고리츠다이가쿠호진 | Ampk 활성화 및/또는 chop 억제에 의한 치료가 가능한 질환 및 장애의 치료를 위한 sephin1 및 관련 화합물 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1223492A (en) | 1967-10-13 | 1971-02-24 | American Home Prod | Guanidines |
| US3541218A (en) * | 1969-06-18 | 1970-11-17 | Lilly Co Eli | Omicron-fluorobenzylaminoguanidine for diabetes |
| SE7607653L (sv) | 1976-07-05 | 1978-01-06 | Haessle Ab | Substituerade triazoler |
| WO1993003714A2 (en) * | 1991-08-27 | 1993-03-04 | The Upjohn Company | Method for treatment of metabolic disorders |
| DE793646T1 (de) * | 1994-11-23 | 1999-12-30 | Pharmacia & Upjohn Co., Kalamazoo | Carboxylierte aminoguanidine zum behandlung von insulin-unabhängigem diabetes mellitus |
| US6335339B1 (en) | 1998-01-13 | 2002-01-01 | Scriptgen Pharmaceuticals, Inc. | Triazine antiviral compounds |
| WO2001025192A1 (en) | 1999-10-06 | 2001-04-12 | Melacure Therapeutics Ab | Guanidine derivatives and their use in the production of a medicament for blocking xanthine oxidase/dehydrogenase |
| GB0019357D0 (en) * | 2000-08-07 | 2000-09-27 | Melacure Therapeutics Ab | Novel phenyl guanidines |
| US6518269B1 (en) | 2000-07-28 | 2003-02-11 | University Of Arizona Foundation | Cancer treatment |
| GB0019359D0 (en) | 2000-08-07 | 2000-09-27 | Melacure Therapeutics Ab | Novel guanidines |
| FR2812812B1 (fr) | 2000-08-08 | 2002-10-11 | Philippe Gorny | Medicament destine notamment a combattre les dysfonctions sexuelles |
| KR20060088885A (ko) * | 2003-09-25 | 2006-08-07 | 아카디아 파마슈티칼스 인코포레이티드 | 뉴로펩티드 ｆｆ 리셉터 2의 작용제를 이용한 신경병증성통증 치료 방법 |
| CN1875271A (zh) * | 2003-09-25 | 2006-12-06 | 阿卡蒂亚药品公司 | 用神经肽ff受体2激动剂治疗神经痛 |
| EP1908464A1 (en) * | 2006-10-04 | 2008-04-09 | Centre National De La Recherche Scientifique (Cnrs) | Use of chlorine guanabenz derivatives for treating polyglutamine expansion associated diseases |
| EP1908465B1 (en) * | 2006-10-04 | 2009-04-29 | Centre National De La Recherche Scientifique (Cnrs) | Use of chlorine guanabenz derivatives for treating prion-based diseases |
| WO2008091681A2 (en) | 2007-01-23 | 2008-07-31 | Housey Gerard M | Theramutein modulators |
| US20120202814A1 (en) | 2009-10-02 | 2012-08-09 | Università Degli Studi Di Siena | Compounds with ddx3 inhibitory activity and uses thereof |
| WO2011097607A1 (en) | 2010-02-08 | 2011-08-11 | Southern Research Institute | Anti-viral treatment and assay to screen for anti-viral agent |
| US9321735B2 (en) | 2010-07-20 | 2016-04-26 | Vestaron Corporation | Insecticidal triazines and pyrimidines |
| WO2012048330A2 (en) * | 2010-10-08 | 2012-04-12 | The Mclean Hospital Corporation | Treatment of motor neuron disease |
| GB201300435D0 (en) | 2013-01-10 | 2013-02-27 | Medical Res Council | Benzylideneguanidine Derivatives and Therapeutic Use for the Treatment of Protein Misfolding Diseases |
-
2013
- 2013-01-10 GB GBGB1300435.3A patent/GB201300435D0/en not_active Ceased
-
2014
- 2014-01-10 US US14/760,350 patent/US9682943B2/en active Active
- 2014-01-10 DK DK14700310.7T patent/DK2943467T3/en active
- 2014-01-10 CA CA2896976A patent/CA2896976C/en active Active
- 2014-01-10 ES ES16172383T patent/ES2831453T3/es active Active
- 2014-01-10 WO PCT/EP2014/050422 patent/WO2014108520A1/en not_active Ceased
- 2014-01-10 RU RU2015127827A patent/RU2654910C2/ru active
- 2014-01-10 PL PL14700310T patent/PL2943467T3/pl unknown
- 2014-01-10 EP EP16172383.8A patent/EP3115357B1/en active Active
- 2014-01-10 HU HUE14700310A patent/HUE030848T2/hu unknown
- 2014-01-10 AU AU2014204831A patent/AU2014204831C1/en active Active
- 2014-01-10 HR HRP20161208TT patent/HRP20161208T1/hr unknown
- 2014-01-10 MX MX2015008977A patent/MX370491B/es active IP Right Grant
- 2014-01-10 CN CN201480004604.1A patent/CN105189452B/zh active Active
- 2014-01-10 PT PT147003107T patent/PT2943467T/pt unknown
- 2014-01-10 RS RS20160798A patent/RS55185B1/sr unknown
- 2014-01-10 LT LTEP14700310.7T patent/LT2943467T/lt unknown
- 2014-01-10 EP EP14700310.7A patent/EP2943467B1/en active Active
- 2014-01-10 ES ES14700310.7T patent/ES2594378T3/es active Active
- 2014-01-10 SI SI201430063A patent/SI2943467T1/sl unknown
- 2014-01-10 JP JP2015552060A patent/JP6276289B2/ja active Active
- 2014-01-10 KR KR1020157019864A patent/KR102166665B1/ko active Active
-
2015
- 2015-06-25 IL IL239629A patent/IL239629B/en active IP Right Grant
-
2017
- 2017-03-23 US US15/467,613 patent/US10100020B2/en active Active
- 2017-12-05 AU AU2017272151A patent/AU2017272151B2/en active Active
-
2018
- 2018-08-31 US US16/119,445 patent/US10526297B2/en active Active
-
2019
- 2019-11-25 US US16/694,694 patent/US10954198B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016504400A5 (enExample) | ||
| RU2015127827A (ru) | Производные бензилиденгуанидина и их терапевтическое применение для лечения заболеваний, связанных с неправильным сворачиванием белков | |
| JP2017509586A5 (enExample) | ||
| AR122902A2 (es) | Compuestos terapéuticamente activos y sus métodos de preparación | |
| JP2017071634A5 (enExample) | ||
| JP2016506960A5 (enExample) | ||
| SI3009431T1 (en) | 2- (2,4,5-substituted-anilino) pyrimidine derivatives, as EGFR modulators useful for the treatment of cancer | |
| JP2015520769A5 (enExample) | ||
| JP2016515561A5 (enExample) | ||
| JP2014521688A5 (enExample) | ||
| JP2013537203A5 (enExample) | ||
| JP2016503797A5 (enExample) | ||
| JP2016506961A5 (enExample) | ||
| PE20141282A1 (es) | Derivados de 8-carbamoil-2-(2,3-pirid-6-ilo di sustituido)-1,2,3,4-tetrahidroisoquinolina como agentes inductores de la apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes | |
| JP2017533968A5 (enExample) | ||
| JP2013533879A5 (enExample) | ||
| AR097082A1 (es) | Compuestos terapéuticamente activos y sus métodos de uso | |
| JP2014511891A5 (enExample) | ||
| JP2014511892A5 (enExample) | ||
| JP2016506962A5 (enExample) | ||
| JP2017504635A5 (enExample) | ||
| JP2016505614A5 (enExample) | ||
| JP2016507575A5 (enExample) | ||
| SA519401322B1 (ar) | مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2 | |
| JP2016531126A5 (enExample) |